Published in J Transl Int Med on September 23, 2016
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19
A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays (2000) 3.31
Tumor-induced osteomalacia. Endocr Relat Cancer (2011) 3.13
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation (2015) 1.86
Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci (2009) 1.52
LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging (2012) 1.35
Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail (2014) 1.15
The uses and limitations of end-systolic indexes of left ventricular function. Circulation (1984) 1.07
Left ventricular and left atrial dimensions and volumes: comparison between dual-source CT and echocardiography. Invest Radiol (2008) 0.97
Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One (2013) 0.95
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant (2013) 0.89
FGF23 beyond mineral metabolism: a bridge to cardiovascular disease. Clin J Am Soc Nephrol (2011) 0.87
Impact of hemodialysis, left ventricular mass and FGF-23 on myocardial mechanics in end-stage renal disease: a three-dimensional speckle tracking study. Int J Cardiovasc Imaging (2014) 0.82
Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis. Ther Apher Dial (2013) 0.81
Fibroblast growth factor-23 and interleukin-6 are risk factors for left ventricular hypertrophy in peritoneal dialysis patients. J Cardiovasc Med (Hagerstown) (2012) 0.79
Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. Pediatr Nephrol (2015) 0.77
Classification of left ventricular size: diameter or volume with contrast echocardiography? Open Heart (2014) 0.77
Risk factors: Levels of FGF23 predict outcomes in advanced CKD. Nat Rev Nephrol (2011) 0.77
From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter? Circulation (2015) 0.77